TY - JOUR
T1 - The critical role of the central nervous system (pro)renin receptor in regulating systemic blood pressure
AU - Xu, Quanbin
AU - Jensen, Dane D.
AU - Peng, Hua
AU - Feng, Yumei
N1 - Publisher Copyright:
© 2016
PY - 2016/8/1
Y1 - 2016/8/1
N2 - The systemic renin–angiotensin system (RAS) has long been recognized as a critically important system in blood pressure (BP) regulation. However, extensive evidence has shown that a majority of RAS components are also present in many tissues and play indispensable roles in BP regulation. Here, we review evidence that RAS components, notably including the newly identified (pro)renin receptor (PRR), are present in the brain and are essential for the central regulation of BP. Binding of the PRR to its ligand, prorenin or renin, increases BP and promotes progression of cardiovascular diseases in an angiotensin II-dependent and -independent manner, establishing the PRR a promising antihypertensive drug target. We also review the existing PRR blockers, including handle region peptide and PRO20, and propose a rationale for blocking prorenin/PRR activation as a therapeutic approach that does not affect the actions of the PRR in vacuolar H+-ATPase and development. Finally, we summarize categories of currently available antihypertensive drugs and consider future perspectives.
AB - The systemic renin–angiotensin system (RAS) has long been recognized as a critically important system in blood pressure (BP) regulation. However, extensive evidence has shown that a majority of RAS components are also present in many tissues and play indispensable roles in BP regulation. Here, we review evidence that RAS components, notably including the newly identified (pro)renin receptor (PRR), are present in the brain and are essential for the central regulation of BP. Binding of the PRR to its ligand, prorenin or renin, increases BP and promotes progression of cardiovascular diseases in an angiotensin II-dependent and -independent manner, establishing the PRR a promising antihypertensive drug target. We also review the existing PRR blockers, including handle region peptide and PRO20, and propose a rationale for blocking prorenin/PRR activation as a therapeutic approach that does not affect the actions of the PRR in vacuolar H+-ATPase and development. Finally, we summarize categories of currently available antihypertensive drugs and consider future perspectives.
KW - (Pro)renin receptor
KW - (Pro)renin receptor antagonists
KW - Antihypertensive drugs
KW - Brain
KW - Hypertension
KW - Prorenin
UR - http://www.scopus.com/inward/record.url?scp=84975165515&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975165515&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2016.04.006
DO - 10.1016/j.pharmthera.2016.04.006
M3 - Review article
C2 - 27113409
AN - SCOPUS:84975165515
SN - 0163-7258
VL - 164
SP - 126
EP - 134
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
ER -